68 related articles for article (PubMed ID: 17273825)
1. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
[TBL] [Abstract][Full Text] [Related]
3. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
Hensley ML; Blessing JA; Mannel R; Rose PG
Gynecol Oncol; 2008 Jun; 109(3):329-34. PubMed ID: 18534250
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Blessing JA; Degeest K; Abulafia O; Rose PG; Homesley HD
Gynecol Oncol; 2008 Jun; 109(3):323-8. PubMed ID: 18394689
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
Gadgeel SM; Wozniak A; Ruckdeschel JC; Heilbrun LK; Venkatramanamoorthy R; Chaplen RA; Kraut MJ; Kalemkerian GP
J Thorac Oncol; 2008 Nov; 3(11):1293-300. PubMed ID: 18978565
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Schneider BJ; Kalemkerian GP; Kraut MJ; Wozniak AJ; Worden FP; Smith DW; Chen W; Gadgeel SM
J Thorac Oncol; 2008 Dec; 3(12):1454-9. PubMed ID: 19057272
[TBL] [Abstract][Full Text] [Related]
8. A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204).
Kunitoh H; Kato H; Tsuboi M; Asamura H; Tada H; Nagai K; Mitsudomi T; Koike T; Nakagawa K; Ichinose Y; Okada M; Shibata T; Saijo N;
Br J Cancer; 2008 Sep; 99(6):852-7. PubMed ID: 18728643
[TBL] [Abstract][Full Text] [Related]
9. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Verschraegen CF; Arias-Pulido H; Lee SJ; Movva S; Cerilli LA; Eberhardt S; Schmit B; Quinn R; Muller CY; Rabinowitz I; Purdy M; Snyder D; Bocklage T
Ann Oncol; 2012 Mar; 23(3):785-790. PubMed ID: 21746804
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.
Bhalla S; Fattah FJ; Ahn C; Williams J; Macchiaroli A; Padro J; Pogue M; Dowell JE; Putnam WC; McCracken N; Micklem D; Brekken RA; Gerber DE
Lung Cancer; 2023 Aug; 182():107291. PubMed ID: 37423058
[TBL] [Abstract][Full Text] [Related]
11. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Mora J; Castañeda A; Perez-Jaume S; Lopez-Pousa A; Maradiegue E; Valverde C; Martin-Broto J; Garcia Del Muro X; Cruz O; Cruz J; Martinez-Trufero J; Maurel J; Vaz MA; de Alava E; de Torres C
Br J Cancer; 2017 Sep; 117(6):767-774. PubMed ID: 28787430
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Macaulay VM; Middleton MR; Protheroe AS; Tolcher A; Dieras V; Sessa C; Bahleda R; Blay JY; LoRusso P; Mery-Mignard D; Soria JC
Ann Oncol; 2013 Mar; 24(3):784-91. PubMed ID: 23104723
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase III study of docetaxel alone versus docetaxel plus S-1 in patients with previously treated non-small cell lung cancer: JMTO LC09-01.
Atagi S; Daimon T; Okishio K; Komuta K; Okano Y; Minato K; Kim YH; Usui R; Tabata C; Tamura A; Kawahara M
Thorac Cancer; 2023 Oct; 14(29):2941-2949. PubMed ID: 37609677
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study.
Wang Y; Hao Q; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Wu D; Long J; Zhang Z; Fang J
Anticancer Drugs; 2024 Jun; 35(5):412-417. PubMed ID: 38240789
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.
Plummer R; Dean E; Arkenau HT; Redfern C; Spira AI; Melear JM; Chung KY; Ferrer-Playan J; Goddemeier T; Locatelli G; Dong J; Fleuranceau-Morel P; Diaz-Padilla I; Shapiro GI
Lung Cancer; 2022 Jan; 163():19-26. PubMed ID: 34894455
[TBL] [Abstract][Full Text] [Related]
16. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Kelly RJ; Draper D; Chen CC; Robey RW; Figg WD; Piekarz RL; Chen X; Gardner ER; Balis FM; Venkatesan AM; Steinberg SM; Fojo T; Bates SE
Clin Cancer Res; 2011 Feb; 17(3):569-80. PubMed ID: 21081657
[TBL] [Abstract][Full Text] [Related]
17. A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.
Monga V; Swami U; Tanas M; Bossler A; Mott SL; Smith BJ; Milhem M
Cancers (Basel); 2018 Feb; 10(2):. PubMed ID: 29462961
[TBL] [Abstract][Full Text] [Related]
18. [Gemcitabine long-term maintenance chemotherapy benefits patients with survival: a multicenter, real-world study of advanced breast cancer treatment in China].
Yue J; Song GH; Li HP; Sun T; Song LH; Tong ZS; Zhang LL; Song ZC; Ouyang QC; Yang J; Pan YY; Yuan P
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):249-255. PubMed ID: 38494771
[No Abstract] [Full Text] [Related]
19. Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study.
Surmont V; Aerts JG; Tan KY; Schramel F; Vernhout R; Hoogsteden HC; van Klaveren RJ
J Oncol; 2009; 2009():457418. PubMed ID: 19920864
[TBL] [Abstract][Full Text] [Related]
20. Metastatic follicular dendritic cell sarcoma treated with gemcitabine plus docetaxel with an outstanding survival: A case report and review of literature.
Esmati E; Kolahdouzan K
Clin Case Rep; 2021 Jan; 9(1):473-476. PubMed ID: 33489199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
